Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Cynthia Sanchez, Scott Kopetz, Pascal Artru, Muriel Mathonnet, Denis Pezet, Olivier Bouché, Alain R. Thierry, Eric Assenat, Rosine Guimbaud, Christophe Borg, Céline Gavoille, Safia El Messaoudi, Christelle De La Fouchardiere, Jean-Luc Raoul, Marc Ychou, Caroline Mollevi, Brice Pastor
Publikováno v:
Cancer Research. 76:2632-2632
Clinical validation of circulating DNA analysis as liquid biopsy for the detection of point mutations and of the longitudinal metastatic colorectal patient follow up for detecting emergence of resistance to targeted therapy We carried out two clinica
Autor:
Mohit Butaney, Melissa M. Messineo, Cam Anh Tran, Amanda J. Redig, Allison O'Connell, Antonio Calles, Sangeetha Palakurthi, Cloud P. Paweletz, Pasi A. Jänne, Shruti D. Shah, Jihyun Choi, Mosab Ali, Yanan Kuang, Masahiko Yanagita, Paul Kirschmeier, Prafulla C. Gokhale, Man Xu, Atsuko Ogino
Publikováno v:
Cancer Research. 75:1451-1451
Background: Genotype directed treatment is the standard of care for patients with advanced non-small cell lung cancer (NSCLC). However, acquired drug resistance invariably develops. There is a need to develop clinically relevant animal models from pa
Autor:
Heiko Krissel, Kathleen Schostack, Michael Teufel, Barrett H. Childs, Joachim Reischl, Christine Gonschorek, Andrea Hennig, Martina Poethig, Philipp Angenendt, Danny Zhang, Fabricio Souza, Rodrigo Ito
Publikováno v:
Cancer Research. 75:5252-5252
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: In a retrospective analysis performed in a phase II study evaluating efficacy and safety of the MEK-inhibitor refametinib plus sorafenib in Asian patients wi
Autor:
Mahnaz Darvish-Damavandi, Giulia Mentrast, Sarah Barton, Ian Chau, David Watkins, Sheela Rao, Khurum Khan, Naureen Starling, George Vlachogianis, David Cunningham, Nicola Valeri, Andrea Lampis, Ruwaida Begum, Francesco Trevisani, Chiara Braconi, Jens C. Hahne, Nasir Khan, Clare Peckitt, Annette Bryant
Publikováno v:
Cancer Research. 75:3589-3589
Background: AE-mABs (cetuximab and/or panitumumab) have been approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Indeed, previous studies have identified mutations (MTs)/amplifications in RAS/RAF/MEK k
Autor:
Alexander M.M. Eggermont, M. Thomas, Janine Wechlser, Nyam Kamsu-Kom, Christine Mateus, Emilie Routier, Ludovic Lacroix, H. Cazenave, Séverine Roy, Lise Boussemart, Isabelle Girault, Caroline Robert, Stéphan Vagner, Gorana Tomasic, Michel Favre
Publikováno v:
Cancer Research. 74:934-934
INTRODUCTION : BRAF inhibitors (BRAFI) are affective anti-melanoma agents in V600BRAF mutant melanoma but have one major adverse event, the paradoxical activation of MAPK pathway in WT BRAF cells, which favors the emergence of benign, borderline and
Autor:
Pedro R. Lowenstein, Daniel Thomas, Alexandra Calinescu, Rosie Lemons, Marta Dzaman, Maria G. Castro, Carl Koschmann
Publikováno v:
Cancer Research. 74:995-995
Pediatric glioblastoma (GBM) remains one of the most difficult childhood tumors to treat, and most patients will die within the first two years of receiving this diagnosis. ATRX is a histone chaperone protein that is mutated primarily in adolescent G
Autor:
Melissa Wilson, Fengmin Zhao, Richard Letrero, Katherine L. Nathanson, David L. Rimm, John M. Kirkwood, Keith T. Flaherty, Harriet M. Kluger, Sandra J. Lee, Kurt D'Andrea
Publikováno v:
Cancer Research. 72:5557-5557
The BRAF kinase, a member of the MAP kinase pathway, has emerged as an attractive molecule to target in melanoma. In an initial attempt to target BRAF in melanoma, a randomized, phase III trial (ECOG 2603) of carboplatin, paclitaxel, and sorafenib ve